{"entity":{"id":"nct07743632","kind":"trial","name":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC","aka":["NeoASPECT"],"tldr":"A phase 2 trial of carboplatin, docetaxel, doxorubicin, cyclophosphamide and other drugs in triple-negative breast cancer, run by University of Kansas Medical Center, not yet recruiting.","summary":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC is a phase 2, interventional study registered as NCT07743632 by University of Kansas Medical Center, with a registry enrolment figure of 110 participants, started 2026-09 and due to reach its primary completion in 2032-12. Interventions recorded: Carboplatin; Docetaxel; Doxorubicin; Cyclophosphamide; Ivonescimab. Conditions listed: Breast Cancer; Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Histologically confirmed cT1c-T3 N0 or cT1-T3 N1-N2 triple-negative breast cancer\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07743632","url":"https://clinicaltrials.gov/study/NCT07743632"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["carboplatin","docetaxel","doxorubicin","cyclophosphamide","ivonescimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07743632","phase":"2","setting":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC (NeoASPECT)","sponsor":"University of Kansas Medical Center","enrolled":110,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07743632/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}